The underlying anticancer effects of butyrate, an end-product of the intestinal microbial fermentation of dietary fiber, remain elusive. Here, we report that butyrate promotes cancer cell apoptosis by acting as a SIRT3 inhibitor. Butyrate inhibits SIRT3 both in cultured cells and in vitro. Butyrate-induced PDHA1 hyperacetylation relieves the inhibitory phosphorylation of PDHA1 at serine 293, thereby activating an influx of glycolytic intermediates into the tricarboxylic acid (TCA) cycle and reversing the Warburg effect. Meanwhile, butyrate-induced hyperacetylation inactivates complex I of the electron transfer chain and prevents the utilization of TCA cycle intermediates. These metabolic stresses promote apoptosis in hyperglycolytic cancer cells, such as HCT116p53 −/− cells. SIRT3 deacetylates both PDHA1 and complex I. Genetic ablation of Sirt3 in mouse hepatocytes abrogated the ability of butyrate to induce apoptosis. Our results identify a butyrate-mediated anti-tumor mechanism and indicate that the combined activation of PDC and inhibition of complex I is a novel tumor treatment strategy.
INTRODUCTION
Intestinal microbes ferment dietary fibers and produce butyrate, a nontoxic primary energy source for colon epithelial cells. Remarkably, the production of butyrate in intestinal tissue is associated with decreased cancer onset. As a result, butyrate is one of the most intensively studied metabolites, but the underlying molecular mechanisms of butyrate-mediated anticancer properties remain incompletely elucidated. It has been proposed that the ability of butyrate to prevent or treat cancer is potentiated through the induction of apoptosis in various cancer cells. For example, in human gastric cancer cells, butyrate treatment induces death-associated protein kinase (DAPK)-mediated apoptosis. 1 In addition, in HCT116 colorectal cancer cells, butyrate treatment induces stress response-mediated apoptosis. 2 In human colon adenocarcinoma cells, butyrate treatment induces apoptosis through up-regulation of B-cell lymphoma 2 (Bcl-2) and inactivation of Bcl-2-associated X protein (BAX). 3 These mechanisms are plausible because butyrate is a confirmed inhibitor of class I and II histones deacetylases (HDACs) 4, 5 and is among the family of small-molecule HDACs inhibitors that are known to inhibit cancers. [6] [7] [8] Histone deacetylases regulate gene transcription by deacetylating proteins including histone proteins and transcription factors and resulting in modified chromatin structure. Thus, butyrate may cause a variety of changes in the nucleus, including histone acetylation, DNA methylation and the modification of nonhistone proteins. Through these changes, butyrate may elevate the expression level of apoptosis-, inflammatory-and tumorassociated genes.
Reprogrammed metabolism is a hallmark of cancer. 9 In contrast to normally differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis. This type of reprogramming of glycolytic activity versus tricarboxylic acid (TCA) cycle activity is known as the Warburg effect. We identified sirtuin-mediated metabolic acetylation as a conserved regulatory mechanism that coordinates the activities of metabolic pathways. 10, 11 This introduces the possibility that relative glycolytic activity versus TCA cycle activity can be modulated by altering the activity of sirtuins. Remarkably, butyrate was projected and confirmed 12 to inhibit sirtuins. This introduces the possibility that butyrate, in addition to altering the transcription of genes, may also inhibit tumor growth by reversing the Warburg effect, 13 a process that is known to induce apoptosis. 14 The pyruvate dehydrogenase complex (PDC), an enzyme complex that links glycolysis to the TCA cycle, is composed of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and lipoamide dehydrogenase (E3). The E1 enzyme is a heterotetramer with two alpha and two beta subunits, and the E1 alpha 1 (PDHA1) subunit has a key role in the function of the PDC. PDC is often inactivated in tumor cells and is a possible cause of the Warburg effect. 15 Conversely, PDC activation could be a possible strategy to prevent or treat cancer. 16 PDC activity is reportedly regulated by SIRT3-mediated acetylation. 17 Furthermore, SIRT3 is also involved in the regulation of oxidative phosphorylation through the regulation of complex I of the electron transfer chain. It has been reported that Sirt3 deletion in mice results in selective inactivation of complex I by altering the function of NDUFA9, a component of complex I. 18 These studies support a scenario in which butyrate reverses the Warburg effect and induces metabolic stress to induce apoptosis, resulting in increased glycolytic influx and less utilization of TCA cycle intermediates. 1 
MATERIALS AND METHODS

Reagents and antibodies
Butyrate (SIGMA, St Louis, CA, USA), sodium dichloroacetate (SIGMA), nicotinamide (SIGMA), rotenone (MERYER, Shanghai, China), TSA (CST, Danver, MA, USA), PDHA1α-phosphor-Ser293 Antibody (Novus Biologicals, Littleton, CO, USA), PDHA1α antibody (Abmart, Berkeley Heights, NJ, USA), Flag antibody (SIGMA), HA antibody (Santa Cruz, Santa Cruz, CA, USA) and the HIF-1α antibody (ABclone, Shanghai, China) were purchased. The pan-acetylation antibody was generated in-house. 19 Isolation of mouse hepatocytes Primary hepatocytes were isolated from fed adult mice by a modified collagenase method. 20 The cells were plated at a density of 2.5 × 10 5 cells per well on 6-well plates or 1 × 10 5 cells per 24-well plates in M199 medium supplemented with 100 U ml − 1 penicillin, 100 μg ml − 1 streptomycin, 10% FBS, 500 nM dexamethasone (dex; Sangon Biotech, Shanghai, China), 10 nM insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark).
Immunoprecipitation and western blotting
Cells were lysed on ice in NP-40 buffer (0.1-0.5% NP-40, 150 mM NaCl, 50 mM Tris-HCl (pH 7.5)) supplemented with protease inhibitors (PMSF, Aprotinin, Leupeptin, Pepstatin, Sodium trioxovanadate and sodium fluoride). Flag-tagged proteins were immunoprecipitated and washed in NP-40 buffer three times. Standard western blot procedures were followed. Detection of acetylation by western blotting was achieved by using 50 mM Tris (pH 7.5) with 10% (v/v) Tween 20 and 1% peptone (AMRESCO, Fountain Parkway Solon, OH, USA) as a blocking buffer and we diluted primary and secondary antibodies in 50 mM Tris (pH 7.5) with 0.1% peptone. 10 Cell survival and apoptosis assay Apoptosis of cells was determined by using the annexin V-FITC apoptosis detection kit (eBioscience, San Diego, CA, USA) according to the manufacturer's instructions on FACScan (BD Pharmigen, Franklin Lakes, NJ, USA). dichloroacetic acid (DCA, 20 mM), rotenone (300 nM) and butyrate (5 mM) treatments were enforced 24 h before cells were subject to analysis. PDHA1 activity assay PDHA1-Flag and PDHB-myc were co-expressed in either HeLa or HEK293T cells. Cells were lysed on ice with 0.5% NP-40 buffer supplemented with protease inhibitors. PDHA1 was immuno-purified using Flag-beads (SIGMA) and washed with 0.1% NP-40 buffer three times. PDHB co-purified with PDHA1 was quantified by myc-western and was used to normalize PDHA1 activity. The PDHA1 activity assay was performed as described previously. 21 Briefly, in a reaction buffer containing 50 mm KH 2 PO 4 (pH 7), 1 mm MgCl 2 , 2 mm sodium pyruvate, 0.2 mm thiamine diphosphate and 0.1 mm 2,6-dichlorophenolindophenol (2,6-DCPIP), purified PDHA1/PDHB complex was added to initiate the reaction. The reactions were maintained at 30°C. The reaction progression was monitored by measuring the reduction of 2,6-DCPIP at 600 nm on a Thermo Fisher BIOMATE 3S (Waltham, MA, USA) spectrophotometer.
PDC activity assay
The assays were performed using the PDH enzyme activity microplate assay kit (Abcam, Cambridge, UK) according to the manufacturer's instructions. The total PDC activity of HeLa cells treated with 0.5 mM butyrate for 2 h was detected.
Liquid chromatography-Mass Spectrometry (LC-MS) analysis
Cells were treated with butyrate (5 mM) for 6 h and DCA (20 mM) for 24 h. Cells were lysed by immediate addition of 1 ml 60% (v/v) pre-chilled (−80°C) methanol into culture plates, followed by centrifugation for 15 min at 12 000 r.p.m. and 4°C. The supernatant was collected and dried with a concentrator. After drying, the sample was dissolved in 400 μl of H 2 O. Last, the sample was filtered through a 0.22-μm filter before liquid chromatography-mass spectrometry (LC-MS) analysis.
Gas chromatography-Mass spectrometry (GC-MS)
Cells were cultured and harvested as in the gas chromatography-mass spectrometry (GC-MS) assay. After centrifugation, the supernatant were lyophilized, followed by oximatation with 20 mg ml − 1 methoxyamine hydrochloride in pyridine at 30°C for 60 min. The samples were then derivatized in 80 μl of pyridine and 20 μl of N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide (MTBSTFA) at 70°C for 30 min. Derivatized samples were filtrated to remove insoluble particles, and 3 μl of each sample was subjected to GC-MS analysis by employing an HP-5MS column (30 m × 0.25 mm × 0.25 μm) for separation on an Agilent 6890-5973 GC-MS system (Santa Clara, CA, USA). 
Mitochondrion complex I activity assay
Mouse primary hepatocytes and HeLa cells treated with 5 mM butyrate were subjected to this assay. Hepatocytes and HeLa cells were treated for 24 h. The assays were performed using the complex I enzyme activity microplate assay kit (Abcam ab109721) according to the manufacturer's instructions.
Glucose uptake assay
This assay was performed using the glucose uptake assay kit (Colorimetric, Abcam ab136955) according to the manufacturer's instructions. HeLa cells were treated with DCA 20 mM for 24 h and butyrate 5 mM for 24 h.
RT-PCR
RNA from cultured cells was prepared with TransZol (Trans Gen Biotech, Beijing, China), and cDNA was synthesized from 5 μg of RNA using TransScript First-Strand cDNA synthesis Super Mix (Trans Gen Biotech). The primers used were as follows:
TGTCCGTCAGAACCCATGC AAAGTCGAAGTTCCATCGCTC Statistics Statistically significant differences between samples were determined using an unpaired two-tailed Student's t-test.
RESULTS
Butyrate relieves the Warburg effect in cancer cells
Cancer cells metabolically exert the Warburg effect, which is characterized by avid glucose consumption and lactate production under aerobic conditions rather than the channeling of glucose intermediates into the TCA cycle. We observed that when HeLa and HCT116p53 −/− cells were treated with 5 mM butyrate, which is within the physiological concentration range of colorectal tissue, 6 ,7 the lactate production decreased by 65 and 40% compared with that of control groups (Figure 1a ). Butyrate treatment in HeLa cells cultured with DMEM media supplemented with a [1,2-
13 C] glucose tracer resulted in decreased concentrations of glycolytic intermediary metabolites, such as fructose 6-phosphate (F6P), glyceraldehyde 3-phosphate (GAP), phosphoenolpyruvate (PEP), pyruvate and lactate (Figure 1b) . Surprisingly, the concentrations of intermediary TCA metabolites increased significantly, including citrate, succinate, fumarate and malate (Figure 1b) . In the butyrate-treated HCT116p53
−/− cells, we also observed decreased glycolytic metabolites and increased TCA metabolites (Figure 1c) . These results indicate that butyrate elevates the influx from glucose into the TCA cycle and mitigates the Warburg effect in cancer cells. Butyrate activates PDC Tumor cells often partially inactivate the PDC, which is the enzyme complex that links glycolysis to the TCA cycle, thus partially uncoupling glycolysis from the TCA cycle. 15 To investigate how butyrate enhances the connection between glycolysis and the TCA cycle in tumor cells, we first tested whether butyrate activates PDC. We treated both HeLa and HEK293T cells with butyrate and analyzed the phosphorylation level of endogenous PDHA1 at serine 293 (P-S293), which is a key indicator of PDHA1 and PDC activity. 22 We found that butyrate treatment decreased the PDHA1 Figure 3 . Butyrate activates PDC by increasing PDHA1 acetylation. (a) Butyrate decreases PDHA1 P-S293 levels. Endogenous PDHA1 P-S293 levels were probed in lysates of HeLa cells cultured with or without 5 mM butyrate, 20 mM DCA,or NAM (5 mM)/TSA (5 μM). Reprehensive western blots (upper panels) and a summary of densitometric analysis (lower graphs) are shown. (b) Acetylation of PDC subunits is enhanced by butyrate treatment. Acetylation levels of overexpressed and immune-purified subunits of PDC from HeLa cells cultured in the absence or presence of 5 mM butyrate were each probed by a pan-acetyllysine antibody. Reprehensive western blots (upper panels) and a summary of densitometric analysis (lower graphs) are shown. (c) Deacetylase inhibitors blunt the ability of butyrate to decrease P-S293 levels. Endogenous P-S293 levels of HepG2 cells cultured with or without NAM+TSA were probed by western blotting (left). Relative P-S293 levels were quantified by normalizing the densities of P-S293 to the densities of actin (right). (d) Mutations at K131, K321 and K336 residues of PDHA1 decrease PDHA1 P-S293 levels. Levels of P-S293 were determined for purified wild-type, K131Q, K321Q, K336Q and 3KQ PDHA1 mutants, respectively. Reprehensive western blots (left panels) and a summary of densitometric analysis (right graphs) are shown. (e) The P-S293 levels of 3KR are comparable to that of wild-type PDHA1. P-S293 levels of wild-type and 3KR mutant PDHA1 were determined. Reprehensive western blots (left panels) and a summary of densitometric analysis (right graphs) are shown. (f) Acetylation mimetic mutation activates PDHA1. Specific activities of wild-type, 3KQ and 3KR PDHA1 mutants were analyzed. The specific activity of wild type was set as 100%, and the relative activities of mutants were compared with those of the wild-type enzyme.
P-S293 levels in a dose-dependent manner in both cell lines (Figure 2a ), suggesting that butyrate may activate PDC. This notion is further supported by measuring PDHA1 activity, the catalytic subunit of PDC and the activity of intact PDC. PDHA1 purified from either HeLa or HEK293T cells cultured with 5 mM butyrate displayed~50% higher specific catalytic activity compared with PDHA1 obtained from control cells (Figure 2b ), which is consistent with the observation that butyrate diminishes P-S293 inhibition of PDHA1. Moreover, the specific activity of PDC isolated from cultured cells was similar to PDHA1 (Figure 2c ), suggesting Reprehensive western blots (left panels) and a summary of densitometric analysis (right graphs) are shown. (d) SIRT3 deacetylase activity is required for P-S293 regulation. Endogenous levels of P-S293 were determined when either SIRT3 or catalytic-dead SIRT3 H248Y was overexpressed in HeLa cells. Reprehensive western blots (left panels) and a summary of densitometric analysis (right graphs) are shown. (e, f) Butyrate inhibits SIRT3 activity in vitro. A synthetically acetylated K336-containing PDHA1 peptide was subjected to in vitro deacetylation by recombinant SIRT3, and the resulting products were analyzed by MS. Numbers denote the mass of detected peptides. Deacetylated peptides (M/Z: 1971.1) were detected in the SIRT3 supplemented reaction system. (g) Butyrate treatment did not change PDHA1 P-S293 levels in Sirt3 − / − mouse hepatocytes. Endogenous PDHA1 P-S293 levels were measured in hepatocytes from Sirt3 − / − mice and control mice treated with or without butyrate. Reprehensive western blots (left panels) and a summary of densitometric analysis (right graphs) are shown.
that butyrate activates PDC activity and confirming that butyrate activates PDHA1. These results, together with the observation that butyrate treatment decreases glycolytic metabolic flux and increases TCA metabolic flux (Figures 1b and c) , confirm that butyrate activates PDC.
Butyrate activates PDC by increasing PDHA1 acetylation Previous reports have shown that acetylation inactivates PDC. 17 We thus measured the changes in acetylation and activity of PDHA1 and PDC on butyrate treatment. Like DCA, a wellestablished PDC activator, treatment with butyrate leads to reduced PDHA1 P-S293 level (Figure 3a) . Meanwhile, treating the cultured cells with a mix of general deacetylase inhibitors, nicotinamide/trichostatin A (NAM/TSA), also reduced PDHA1 P-S293 levels (Figure 3a) . These results suggested that acetylation activates rather than inactivates PDC. This finding was further substantiated by the observation that butyrate treatment increased the acetylation of all PDC subunits, namely, E1 (PDHA and PDHB), E2 (DLAT) and E3 (DLD) (Figure 3b) . Moreover, the ability of butyrate to decrease P-S293 levels was abrogated in the presence of NAM/TSA (Figure 3c ), further confirming that acetylation activates PDC. To elucidate the molecular mechanisms of butyrate-mediated PDHA1 acetylation and activation, we screened all known PDHA1 acetylation sites to assess their ability to decrease P-S293 levels. Among a number of acetylation sites we identified in PDHA1, we also substituted lysine 313 (K313), lysine 321 (K321) and lysine 336 (K336) with the acetylation mimetic glutamine (K/Q) and found that the PDHA1 P-S293 levels were reduced. On converting all three lysine residues to glutamine (PDHA1 3KQ ), we observed a synergistic decrease in PDHA1 P-S293 levels (Figure 3d ). In contrast, replacing these lysines with nonacetylable lysine memetic arginines (PDHA1 3KR ) resulted in negligible changes in P-S293 levels (Figure 3e) . Furthermore, purified PDHA1 3KQ was 42% more active than wild-type PDHA1, whereas the activity of PDHA1 3KR was comparable to that of wildtype PDHA1 (Figure 3f ). These results confirmed that these three lysine residues are responsible for acetylation-mediated activation of PDHA1.
Butyrate increases PDHA1 acetylation by inhibiting SIRT3 To verify that acetylation activates PDHA1, we identified the corresponding deacetylase for PDHA1. PDHA1 acetylation could only be increased by treatment with the class III deacetylase inhibitor NAM but not by treatment with the class I, II and VI deacetylase inhibitor TSA (Figure 4a ), suggesting that PDHA1 is deacetylated by an NAD + -dependent sirtuin family deacetylase. Given that PDHA1 is located in the mitochondria, we tested the ability of mitochondrial sirtuins (SIRT3, SIRT4 and SIRT5) to alter endogenous P-S293. In the co-immunoprecipitation assays, we found that only SIRT3 binds to PDHA1 (Figure 4b) . Moreover, overexpression of SIRT3, but not that of SIRT4 or SIRT5, increased P-S293 levels (Figure 4c ), suggesting that SIRT3 is a deacetylase for PDHA1. Furthermore, overexpression of SIRT3, but not a catalytically dead mutant SIRT3 H248Y , 23 increased P-S293 levels (Figure 4d ), demonstrating that increased SIRT3 catalytic activity is the cause of the increased P-S293 levels in this system. In addition, butyrate inhibits SIRT3 activity, with a median inhibitory concentration (IC 50 ) of 10.08 mM in vitro (Figure 4e ). Next, we confirmed the ability of SIRT3 to deacetylate PDHA1 by demonstrating that recombinant SIRT3 deacetylates a synthetic K336 Ac -containing PDHA1 peptide in vitro (Figure 4f ). Importantly, butyrate treatment failed to induce PDHA1 acetylation and decreased P-S293 levels in hepatocytes from Sirt3 −/− mice (Figure 4g ). These data demonstrate that SIRT3 is the major, if not only, deacetylase for PDHA1.
Butyrate inhibits complex I by inhibiting SIRT3 SIRT3 has an important role in regulating energy homeostasis. It was previously reported that Sirt3 knockout in mice selectively inactivates complex I by altering the function of NDUFA9, a component of complex I. 18 We observed that treatment with both butyrate and deacetylase inhibitors decreased the activity of complex I in either HeLa or HEK293T cells (Figure 5a ), suggesting that the activity of human complex I is negatively regulated by acetylation. Furthermore, knockdown of SIRT3 in HeLa cells reduced complex I activity and blunted the ability of butyrate to inhibit the activity of complex I, whereas SIRT3 reintroduction increased complex I activity and partially restored the ability of butyrate to inhibit complex I (Figure 5b ). Altogether, these results confirm that butyrate inactivates complex I by inhibiting SIRT3.
Butyrate promotes glycolytic cell apoptosis by activating PDC and inhibiting complex I Complex I inhibition by compounds such as by rotenone induces apoptosis. 24 Butyrate treatment also increases cell apoptosis. [25] [26] [27] [28] To simulate the apoptosis-inducing effects of butyrate-induced PDC activation and complex I inhibition, we measured the apoptosis rate in HeLa cells when complex I was inhibited by rotenone and PDC was activated by DCA. Either DCA treatment or rotenone treatment lead to mild apoptosis. Surprisingly, rotenonetreated cells were extremely sensitive to the activation of PDC by DCA, and we observed increased rates of apoptosis (Figure 6a ). In the presence of 300 nM rotenone, 15 mM DCA treatment increased apoptosis by more than 100% and 30 mM DCA treatment increased apoptosis by more than 400% (Figure 6a ), suggesting that PDC activation-induced apoptosis is potentiated by complex I inhibition. Moreover, treatment with 300 nM rotenone and inactivation of PDC by either overexpression of PDK1 or SIRT3 decreased apoptosis in HeLa cells (Figure 6b ). Taken together, these results demonstrate that when complex I is inhibited, increased influx of TCA intermediates causes severe apoptosis. Therefore, we reasoned that glycolytic tumor cells would be more prone to butyrate-induced apoptosis than normal cells because more TCA cycle metabolites would be influx after complex I inhibition. Because HCT116p53 −/− cells are more glycolytic than HCT116p53
+/+ cells due to the lack of negative glycolytic regulation by p53, 29 we next compared the apoptotic rates of HCT116p53 +/+ and HCT116p53 −/− cells in response to butyrate treatment (Figure 6c ). At a concentration of 10 mM, butyrate treatment induced nearly 180% more apoptosis in HCT116p53 +/+ cells. 30 Finally, SIRT3 knockdown increased apoptosis in HeLa cells but blunted butyrate-induced apoptosis from 160 to~50% (Figure 6e ), confirming that butyrate induces apoptosis via the inhibition of SIRT3. 
DISCUSSION
Our study is the first to report that butyrate exerts anticancer efficacy by inhibiting the type III deacetylase SIRT3. In vitro, butyrate treatment inhibited the ability of SIRT3 to deacetylate a synthetic acetylated K336-containing PDHA1 peptide. In cultured cells, butyrate treatment increased the pan-acetylation levels of mitochondrial proteins PDHA1 and complex I. At molecular level, butyrate treatment induced acetylation on the K313, K321 and K336 residues of PDHA1, decreased PDHA1 P293 levels, activated PDC and increased the influx of glucose intermediates into mitochondria. Meanwhile, butyrate treatment induced acetylation on complex I, thus inactivating complex I and preventing TCA intermediates from being converted to ATP. The net outcome of butyrate treatment is therefore to create metabolic stress that promotes apoptosis and inhibits the growth of cancer cells (Figure 7) .
Butyrate is a primary end-product of microbial fermentation of dietary fiber in the intestine. Our findings provide plausible explanations for the importance of balancing the intestinal microbiome and consuming dietary fibers. We have also shown that butyrate could reduce the number of transformed cells by promoting their apoptosis through concerted activation of PDC and inactivation of complex I. Our findings at least partially explain the anti-tumor effects of butyrate and can be further explored. For example, exaggerating complex I inhibition and PDC activation to induce more severe apoptosis in highly glycolytic cancer cells could serve as a cancer preventive or treatment strategy. 
